Denise Yates (0000-0003-1039-515X)

Personal information

Biography

At NIBR since 2008, Denise Yates has leads effort focused on developing the strategy and implementation of clinical imaging in the early phase proof of concept human trials for the Translational Medicine Cardiovascular, Respiratory and New Indications groups. In her role, she has lead the collaborative efforts with expert imaging centers in Radiology and Cardiology departments of high profile academic centers to implement state of the art technologies for robust Phase II clinical trials. In a role as Therapeutic Area head for Biomarker Development Cardiovascular and Metabolism she supports the biomarker development portfolio for cardiovascular trials that includes genomic, proteomic, metabolic and novel technology approaches. Prior to joining Novartis, Dr. Yates was a faculty member of Department of Radiology, Massachusetts General Hospital at the Martinos Center for Biomedical Imaging and Assistant Professor, Harvard Medical School since 1999. She has served as scientific reviewer for the American Heart Association, journal reviewer for Circulation, CV imaging and has authored over 60 publications and conference proceedings.

Activities

Collapse all

Novartis Institutes for BioMedical Research Inc: Cambridge, MA, US

2008-11-19 to present | CVM Therapeutic Area Head (Biomarker Development)

Employment

Denise Yates

https://orcid.org/0000-0003-1039-515X

Personal information

Countries

Biography

Activities

Employment (2)

Novartis Institutes for BioMedical Research Inc: Cambridge, MA, US

Massachusetts General Hospital: Boston, Massachusetts, US

Education and qualifications (2)

University of North Carolina System: Chapel Hill, NC, US

American University: Washington, DC, US

Works (21)

Data from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Data from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial

Aptamer Proteomics for Biomarker Discovery in Heart Failure With Reduced Ejection Fraction

Coronary Artery Disease Polygenic Risk Score Identifies Patients at Higher Risk for Recurrent Cardiovascular Events in the CANTOS Trial

Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial

<p>Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial</p>

Variability of MRI Aortic Stiffness Measurements in a Multicenter Clinical Trial Setting: Intraobserver, Interobserver, and Intracenter Variability of Pulse Wave Velocity and Aortic Strain Measurement